insomnia
Instructed in new medication Temazepam to manage insomnia. In addition, warned of possible S/E such as drowsiness, dizziness, lethargy, disturbed coordination, daytime sedation, confusion, nightmares, vertigo, euphoria, weakness, headache, fatigue, nervousness, anxiety, depression, blurred vision, diarrhea, nausea, dry mouth, physical and psychological dependence. Avoid alcohol during therapy. Caution when performing activities that require mental alertness or physical coordination. Instructed not to discontinue drug abruptly if it is taken for 1 month or longer.
Instructed in new medication Amitriptyline to manage depression. In additon, warned of possible S/E such as coma, seizures, hallucinations, delusions, disorientation, ataxia, tremor, peripheral neuropathy, anxiety, insomnia, restlessness, drowsiness, dizziness, weakness, fatigue, headache, extrapyramidal reactions, MI, stroke, arrhythmias, heart block, orthostatic hypotension, tachycardia, ECG changes, hypertension, edema, blurred vision, tinnitus, mydriasis, increased intraocular pressure, dry mouth, nausea, vomiting, anorexia, epigastric distress, diarrhea, constipation, paralytic ileum, urine retention, agranulocytosis, thrombocytopenia, leukopenia, eosinophilia, hypoglycemia, hyperglycemia, rash, urticaria, photosensitivity, diaphoresis and hypersensitivity reaction. Instructed to take full dose at bedtime but warned patient of possible morning orthostatic hypotension. Avoid alcohol during drug therapy. Consult MD before taking other medications. Avoid activities that require alertness and good psychomotor coordination until CNS effects of drug are known. Drowsiness and dizziness usually subside after a few weeks. Dry mouth may be relieved with sugarless hard candy or gum. Saliva substitutes may be needed. Instructed to use a sun block, wear protective clothing and avoid prolonged exposure to strong sunlight. To prevent photosensitivity reactions. Do not stop drug therapy abruptly.
Instructed in new medication Atorvastatin to reduce cholesterol levels. In addition, warned of possible S/E such as headache, asthenia, insomnia, peripheral edema, rhinitis, pharyngitis, sinusitis, abdominal pain, dyspepsia, flatulence, nausea, constipation, diarrhea, urinary tract infection, arthritis, arthralgia, myalgia, bronchitis, rash, infection, flu-like syndrome, and allergic reaction.
Instructed in new medication Synthroid and in S/E such as nervousness, insomnia, tremor, headache, fever, tachycardia, palpitations, arrhythmias, angina pectoris, cardiac arrest, diarrhea, vomiting, menstrual irregularities, weight loss, allergic skin reactions, diaphoresis or heat intolerance.
Instructed in new medication Levaquin to manage infection. In addition, warned of possible S/E such as headache, insomnia, dizziness, encephalopathy, chest pain, palpitations, vasodilation, nausea, diarrhea, vomiting, abdominal pain, dyspepsia, flatulence, vaginitis, eosinophilia, hypoglycemia, back pain, tendon rupture, rash, pruritus, hypersensitivity reactions, etc. Instructed to take drug as prescribed, even if signs and symptoms disappear. Take drug with plenty of fluids and avoid antacids, sucralfate, and products containing iron or zinc for at least 2 hours before and after each dose. Avoid excessive sunlight, use sun block, and wear protective clothing when outdoors. Stop drug usage and notify prescriber if rash or other S/S of hypersensitivity develop. Notify prescriber if patient experiences pain or inflammation. Tendon rupture can occur with drug. Instructed to Diabetic patient to monitor glucose level and notify prescriber if a hypoglycemia reaction occurs. Notify prescriber if loose stools or diarrhea occurs.
Instructed in new medication Albuterol to prevent or treat bronchospasm in patients with reversible obstructive airway disease. In addition, warned of possible S/E such as tremor, nervousness, dizziness, insomnia, headache, hyperactivity, weakness, CNS stimulation, malaise, tachycardia, palpitations, hypertension, dry and irritated nose and throat (with inhaled form), nasal congestion, epistaxis, hoarseness, heartburn, nausea, vomiting, anorexia, bad taste in mouth, increased appetite, hypokalemia, muscle cramps, bronchospasm, cough, wheezing, dyspnea, bronchitis, increased sputum or hypersensitivity reactions. Warned patient about possibility of paradoxical bronchospasm. If this occurs, discontinue drug immediately. If more than one inhalation is ordered, instructed to wait at least 2 minutes before repeating procedure. Use of an aero chamber may improve drug delivery to the lungs. If steroid inhaler used, advised to use the bronchodilator first and then advised to wait about 5 minutes before using the steroid. This allows the bronchodilator to open the air passages for maximum effectiveness. Advised to remove canister and wash inhaler with warm, soapy water at least once a week.
Instructed in new medication Aricept to manage moderate dementia of the Alzheimer type. In addition, warned of possible S/E such as headache, insomnia, dizziness, fatigue, depression, abnormal dreams, somnolence, seizures, tremor, irritability, paresthesia, aggression, vertigo, ataxia, restlessness, abnormal crying, nervousness, aphasia, syncope, pain, chest pain, hypertension, vasodilation, atrial fibrillation, hot flashes, hypotension, cataract, blurred vision, eye irritation, sore throat, nausea, diarrhea, vomiting, anorexia, fecal incontinence, GI bleeding, bloating, epigastric pain, frequent urination, ecchymosis, weight loss, dehydration, muscle cramps, arthritis, toothache, bone fracture, dyspnea, bronchitis, pruritus, urticaria, diaphoresis, influenza, and increased libido. The drug does not alter the underlying degenerative disease but can temporarily stabilize or relieve symptoms. Effective therapy depends on taking drug at regular intervals. Instructed to take drug in the evening, just before bedtime. Immediately report significant adverse effects or changes in overall health status. Inform health care team that patient is taking drug before he receives anesthesia. Avoid OTC cold or sleep remedies because of the potential for increased anticholinergic effects.
Instructed patient on new medication Ciprofloxacin HCL, which is used to manage tract infection. In addition, warned of possible S/E, such as, headache, restlessness, tremor, dizziness, fatigue, drowsiness, insomnia, depression, light-headedness, confusion, hallucinations, seizures, paresthesia, thrombophlebitis, edema, nausea, diarrhea, vomiting, abdominal pain or discomfort, oral candidiasis, pseudomembranous colitis, dyspepsia, flatulence, constipation, crystalluria, interstitial nephritis, eosinophilia, leukopenia, neutropenia, thrombocytopenia, arthralgia, arthropathy, joint or back pain, joint inflammation, joint stiffness, tendon rupture, aching, neck or chest pain, rash, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, burning, pruritus, erythema, hyperpigmentation.
Instructed on the importance of taking Levothyroxine as a single dose, preferably before breakfast, to prevent insomnia.
Instructed on some signs/symptoms of depression, such as: guilty feelings and insomnia or excessive sleeping, among others.